52423-62-8

Basic information

• Product Name: 2-BroMo-1-Cyclopentyl-Ethanone
• Synonyms: 2-BroMo-1-Cyclopentyl-Ethanone
• CAS NO: 52423-62-8
• Molecular Formula: C₇H₁₁BrO
• Molecular Weight: 191.06564
• Mol File: 52423-62-8.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 233°C at 760 mmHg
• Flash Point: 77.1°C
• Appearance: /
• Density: 1.435g/cm³
• Vapor Pressure: 0.0574mmHg at 25°C
• Refractive Index: 1.512
• CAS DataBase Reference: 2-BroMo-1-Cyclopentyl-Ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BroMo-1-Cyclopentyl-Ethanone(52423-62-8)
• EPA Substance Registry System: 2-BroMo-1-Cyclopentyl-Ethanone(52423-62-8)

Safety Data

• Hazardous Substances Data: 52423-62-8(Hazardous Substances Data)

Usage

InChI:InChI=1/C7H11BrO/c8-5-7(9)6-3-1-2-4-6/h6H,1-5H2

Upstream product

• 6004-60-0 1-cyclopentylethanone 

Downstream Products

• 152665-68-4 [1-(2-Cyclopentyl-2-oxo-ethyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-carbamic acid benzyl ester 
• 155412-20-7 [1-(2-Cyclopentyl-2-oxo-ethyl)-2-oxo-5-pyridin-3-yl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-carbamic acid benzyl ester 
• 152665-83-3 [1-(2-Cyclopentyl-2-oxo-ethyl)-2-oxo-5-pyridin-2-yl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-carbamic acid benzyl ester 
• 152665-86-6 [1-(2-Cyclopentyl-2-oxo-ethyl)-2-oxo-5-pyridin-4-yl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-carbamic acid benzyl ester 
• 929710-14-5 [5-cyclohexyl-1-(2-cyclopentyl-2-oxo-ethyl)-2-oxo-1,2-dihydro-benzo[e][1,2,4]triazepin-3-yl]-acetic acid ethyl ester 
• 150007-40-2 3-Amino-1-(2-cyclopentyl-2-oxo-ethyl)-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one 
• 155488-19-0 (R)-3-Amino-1-(2-cyclopentyl-2-oxo-ethyl)-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one 

Relevant articles and documents

A focused structure-activity relationship study of psoralen-based immunoproteasome inhibitors

The immunoproteasome is a multicatalytic protease that is predominantly expressed in cells of hematopoietic origin. Its elevated expression has been associated with autoimmune diseases, various types of cancer, and inflammatory diseases. The development of immunoproteasome-selective inhibitors with non-peptidic scaffolds remains a challenging task. Here, we describe a focused series of psoralen-based inhibitors of the β5i subunit of the immunoproteasome with different substituents placed at position 4′. The most promising compound was further evaluated through changes at position 3 of the psoralen ring. Despite a small decrease in the inhibitory potency in comparison with the parent compound, we were able to improve the selectivity against other subunits of both the immunoproteasome and the constitutive proteasome. The most potent compounds discriminated between both proteasome types in cell lysates and also showed a decrease in cytokine secretion in peripheral blood mononuclear cells.

OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF

The present disclosure relates to oxadiazine compounds, pharmaceutical compositions comprising an effective amount of an oxadiazine compound and methods for using an oxadiazine compound in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of an oxadiazine compound.